Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer

The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual disease after neoadjuvant (before surgery) treatment.